Introduction
============

*Proteae* are specific *Enterobacteriaceae* comprising bacterial species present in water, soil or in the intestinal tract of humans and animals. In humans, *Proteae*, and especially *Proteus mirabilis*, are often the cause of urinary tract infections (UTIs; [@B28]). They are otherwise opportunistic pathogens responsible for various infections ranging from minor to life-threatening issues. In veterinary medicine, *P. mirabilis* and other *Proteae* are rarely found as pathogens except as a cause of UTIs in companion animals ([@B4]). This pathology is only rarely treated with extended-spectrum cephalosporins (ESC), and the recommended antibiotics are sulphonamides, aminoglycosides, or fluoroquinolones.

*Proteus mirabilis* is naturally susceptible to β-lactams and β-lactamases inhibitors ([@B35]). In the late 1990s, the emergence of *P. mirabilis* isolates expressing acquired β-lactamases was first reported in France ([@B6]). Extended-spectrum (ESBL) and AmpC β-lactamases are of a critical importance because they both confer resistance to nearly all β-lactams, including ESC. Interestingly, even though the corresponding genes (mostly *bla*~CTX-M-types~ and *bla*~VEB-6~ for ESBL and *bla*~CMY\ -2~ and *bla*~DHA-16~ for AmpC) are generally located on plasmids which allow an easy intra- or inter-species dissemination, several studies revealed chromosome-encoded ESBL/AmpC genes in *P. mirabilis* ([@B34]; [@B16]). These chromosome-encoded genes are often carried by genomic islands (such as the *Salmonella* Genomic Island 1, SGI1) or integrating conjugative elements (ICEs) that may also be transmitted ([@B17]; [@B24]). While ESBL-producing *P. mirabilis* are nowadays commonly isolated from humans, the first CTX-M-55-producing *P. mirabilis* in animals was only reported in 2011 from a macaque imported from Vietnam to France ([@B7]).

Besides, *P. mirabilis* can also carry various genomic islands conferring multidrug resistance. For example SGI1, the genomic island widely disseminated in *Salmonella*, was first identified in a clinical *P. mirabilis* from a diabetic patient from Palestine in 2006 ([@B1]). SGI1 is a site-specific integrative mobilizable element conferring multidrug resistance initially described in *Salmonella enterica* serovar Typhimurium DT104 ([@B2]).

*Salmonella* genomic island 1 is the first MDR genomic island identified in *S. enterica*, and contains a complex class 1 integron, named In104 ([@B14]). Since the identification of SGI1 in *S.* Typhimurium DT104, more than 30 different SGI1 variants carrying different combinations of antimicrobial resistance genes were described so far ([@B14]). The complex In104 integron variants classically possess one or two cassette attachment sites (*attI1*) carrying various resistance gene cassette arrays, contain an IS*6100* element, may contain additional resistance genes, and are bound by 25-bp inverted repeats IRi and IRt ([@B2]) (**Figure [1](#F1){ref-type="fig"}**). In the great majority of these variants, the complex In104 integron or its variants are found always at the same position in the SGI1 scaffold, i.e., between the resolvase gene *res* (also named *tnpR*) and the open reading frame (ORF) S044 at the 3′ end of SGI1 ([@B14]). A few additional variations occurred in the SGI1 backbone of some variants, especially the insertion/deletion created by IS*Vch4* between ORF S005 and S009 that was found in several SGI1 variants (SGI1-H, -Ls, -Ks, -Ps, Qs, -*Pm*ABB, and -*Pm*MAT) in *S. enterica* and *P. mirabilis* ([@B11]; [@B32]).

![**Schematic view of SGI1 in the *Proteus mirabilis* chromosome.** **(A)** Specific genetic traits of the SGI1 structure, the genetic rearrangement due to IS*Vch4*, and the complex class 1 integrons are represented in frames. Genes and ORFs are shown as arrows, with their orientations of transcription indicated by the arrowheads. Black arrows indicate antibiotic resistance genes. White arrows within boxes represent insertion sequence elements. IRi and IRt are 25-bp imperfect inverted repeats defining the integrase and *tni* ends of complex class 1 integrons. The complex class 1 integrons were drawn from PCR mapping results and GenBank accession numbers AF261825 (SGI1), HQ888851 (SGI1-V), AY458224 (SGI1-H), and JX121638 (SGI1-*Pm*ABB). **(B)** Schematic view of PGI1 in the *P. mirabilis* chromosome. PCRs carried out to map the PGI1 backbone and junctions with the chromosome are indicated by thick black bars. Gray and white arrows represent the chromosomal genes and the backbone of the island, respectively.](fmicb-08-00032-g001){#F1}

*Salmonella* genomic island 1 is found integrated most of the time within the last 18 bp of the well-conserved chromosomal *trmE* gene (also named *thdF*). SGI1 is specifically mobilized *in trans* by conjugative plasmids of the IncA/C family ([@B10]). Only this plasmid family has been shown to be able to mobilize SGI1 ([@B9]). The main reason of this specificity is that the SGI1 excision from the chromosome is triggered by the master activator AcaDC encoded by IncA/C conjugative plasmids ([@B5]; [@B19]). Then, as an extrachromosomal form, SGI1 is able to hijack the conjugative apparatus encoded by IncA/C plasmids to be conjugally transferred to a recipient cell ([@B5]).

Since 2006, *P. mirabilis* strains carrying different SGI1 variants have only been reported in China and France ([@B3]; [@B32]; [@B27]). Importantly, the SGI1-V variant, which is specifically found in *P. mirabilis*, harbors the *bla*~VEB-6~ gene and was first reported in a lethal human case in France ([@B31]).

Recently, a new multidrug resistant genomic island named *Proteus* Genomic Island 1 (PGI1) was described in human *P. mirabilis* isolates in France ([@B33]). A specific PGI1 variant, PGI1-*Pm*PEL, was shown to harbor both the *bla*~VEB-6~ gene and the carbapenemase-encoding gene *bla*~NDM-1~ ([@B13]). *P. mirabilis* isolates of animal origin were also shown to carry SGI1 or PGI1. Indeed, SGI1-positive *P. mirabilis* isolates were reported in poultry and swine farms in China ([@B20], [@B21]). In France, we recently described the very first cases of SGI1 (including the VEB-6-producing SGI1-V variant) or PGI1-positive *P. mirabilis* in dogs ([@B29]).

The SGI1/PGI1-positive *P. mirabilis* isolates reported in animals and humans so far were sporadic cases. Considering the apparent emergence of these genetic determinants in *P. mirabilis*, our aim was to investigate the prevalence of SGI1 and PGI1 in *Proteae* of animal origin in France, and to characterize molecularly the collected strains. In line with recent observations that a SGI1-V-carrying *P. mirabilis* clonal population was shared between humans and animals, we also investigated the genetic relationship of those isolates in order to draw hypotheses on a possible transfer between the two populations. Finally, as these islands in *P. mirabilis* isolates were also shown to occasionally capture ESBL or carbapenemase genes, we investigated the global prevalence of those genes in the same collection.

Materials and Methods {#s1}
=====================

Bacterial Strains and Antibiotic Susceptibility Testing
-------------------------------------------------------

Between April, 2013 and February, 2015, a total of 468 clinical non-duplicate *Proteae* isolates (*P. mirabilis*, *n* = 459; *P. vulgaris*, *n* = 1; *P. penneri*, *n* = 1; *Morganella morganii*, *n* = 2; *Providencia rettgeri*, *n* = 4; *P. stuartii*, *n* = 1) were collected from various animal hosts corresponding to distinct and epidemiological unrelated individuals (dogs, *n* = 411; cats, *n* = 25; horses, *n* = 13; bovine, *n* = 7; rabbit, *n* = 3; ovine, *n* = 3; ferret, *n* = 2; snake, *n* = 2; chicken; *n* = 1; bird, *n* = 1) and originating from distant geographical areas throughout France. These isolates were collected through the Resapath, the French antimicrobial resistance surveillance network in animal pathogens^[1](#fn01){ref-type="fn"}^. Identification was performed by peripheral veterinary laboratories and then confirmed at the Anses laboratory in Lyon, France, using Api20E strips (bioMérieux, Marcy l'Etoile, France). Isolates were screened for antibiotic resistance by the disk diffusion method according to the guidelines of the CA-SFM with 30 antibiotics of veterinary or human interest^[2](#fn02){ref-type="fn"}^.

SGI1/PGI1 Detection and PCR Mapping
-----------------------------------

*Salmonella* genomic island 1 detection was performed by PCR amplification with degenerated primers designed in order to amplify all known SGI1 and PGI1 integrase genes (FwintSGI1HR, 5′ATGTTGCGTCAGGCYGAGGC; RvintSGI1HR, 5′GAGTGYCCAAGAAGSCGAGAG). The chromosomal location was confirmed by PCR amplification of the left and right junctions in the chromosome, as previously described ([@B29]). The genetic diversity of SGI1 was assessed by PCR mapping covering the entire island using primers previously described ([@B31], [@B32]). PGI1 detection, chromosomal location, backbone mapping and resistance gene detection were performed by PCR, as previously described (**Figure [1](#F1){ref-type="fig"}**) ([@B33]).

Identification and Genetic Location of ESBL and AmpC Genes
----------------------------------------------------------

β-lactamase genes detection was performed by PCR, as previously described ([@B8]). For the CTX-M-1 group, an additional PCR was performed using external primers (ISEcp1L1, 5′ CAGCTTTTATGACTCG; P2D, 5′ CAGCGCTTTTGCCGTCTAAG) and the amplicons were sequenced.

The chromosomal location of these genes was assessed with the *I-Ceu*I (New England Biolabs, Hertfordshire, UK) technique ([@B22]). After digestion of the complete DNA, DNA fragments were separated by Pulsed-Field Gel Electrophoresis (PFGE) in TBE 0.5 X at 14°C using a CHEF Mapper (Bio-Rad Laboratories, Richmond, CA, USA). Running conditions were 6 V/cm with a switch time of 5.3--49.9 s for 19.7 h. Southern blots were performed by transferring the DNA on a Hybond-N^+^ membrane and hybridizing the membrane with DIG-labeled probes specific for the 23S rDNA, the ESBL (*bla*~VEB-6~, *bla*~CTX-M-1~, or *bla*~CTX-M-15~) and AmpC (*bla*~CMY\ -2~ or *bla*~DHA-16~) genes of interest (see detailed primers in **Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). Probes were prepared by PCR using labeled DIG-dUTP (PCR DIG probe synthesis kit; Roche Diagnostics, Indianapolis, IN, USA). Detection was performed using the DIG DNA Labeling and Detection Kit (Roche Diagnostics) according to the manufacturer's instructions.

The plasmidic location of these genes was assessed by Southern blots on S1-PFGE gels (New England Biolabs, Hertfordshire, UK). Running conditions were 6 V/cm with a switch time of 1--30 s for 20 h. Hybridization was performed as described above for Southern blots on *I-Ceu*I gels, using the same ESBL/AmpC probes and the DIG DNA Labeling and Detection Kit.

Finally, all SGI1/PGI1-positive, ESBL and AmpC strains were analyzed by PCR-based replicon typing (PBRT kit; Diatheva, Fano, Italy) in order to type the plasmids carrying the ESBL/AmpC genes.

Genetic Relationship of the Isolates
------------------------------------

The genetic diversity was investigated by PFGE. DNA plugs were digested with *Sma*I (Promega, Madison, WI, USA) and genomic DNA was separated by CHEF Mapper gel electrophoresis in TBE 0.5 X at 14°C. The running conditions were 6 V/cm with a switch time of 5--20 s for 22 h. *Xba*I-digested *S. enterica* serovar Braenderup strain H9812 was used as size ladder. The DNA patterns were analyzed using BioNumerics software version 4.5 (Applied Maths, Sint-Martens-Latem, Belgium) to construct a phylogenetic tree. Analysis was performed using the Dice coefficient with optimization set at 0.5% and tolerance at 1%.

Results and Discussion
======================

Prevalence and Molecular Characterization of the SGI1/PGI1 Genomic Islands
--------------------------------------------------------------------------

*Salmonella* genomic island 1/*Proteus* genomic island 1-carrying *P. mirabilis* are emerging pathogens in humans and animals. In a recent study, SGI1/PGI1-carrying *P. mirabilis* were reported in animals in France but no large-scale non-biased data on their prevalence were available ([@B29]). Here, we investigated a large collection of 468 *Proteae* isolates of animal origin in France to estimate the prevalence of the SGI1/PGI1 elements. We also assessed the prevalence of resistance to broad-spectrum cephalosporins in those *Proteae* isolates considering that the *bla*~VEB-6~ gene was recurrently reported on the SGI1-V variant in *P. mirabilis* ([@B31]; [@B29]). Among the 468 isolates studied, 17 *P. mirabilis* (17/468, 3.6%) were positive for SGI1 (11 isolates) or PGI1 (6 isolates) by PCR (**Figure [2](#F2){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). They were mostly recovered from dogs (*n* = 13; 13/411, 3.2%), but also from cats (*n* = 2; 2/25, 8%), and horses (*n* = 2; 2/13, 15.4%). While *Proteae* are more frequently isolated from dogs, SGI1/PGI1 elements were more prevalent in cats and horses. This would deserve confirmation due to the low number of isolates collected from these two animal categories.

![**Analysis of *Sma*I-Pulsed-Field Gel Electrophoresis (PFGE) patterns obtained from the relevant *P. mirabilis* isolates.** PFGE profiles were compared using BioNumerics software version 4.5 (Applied Maths) with settings of 0.5% optimization and 1.0% tolerance. DNA of *S. enterica* serovar Braenderup strain H9812 was used as standard size marker in PFGE experiments and as outgroup in analysis ([@B18]). The isolates in bold correspond to previously published profiles included for comparison purposes ([@B29]).](fmicb-08-00032-g002){#F2}

###### 

Antibiotic resistance profiles of *Proteus mirabilis* strains of interest in this study.

  Strain     Isolation date (yyyy/mm/dd)   Host    Geographic area^b^   Pathology                 Antibiotic resistance profile^a^
  ---------- ----------------------------- ------- -------------------- ------------------------- --------------------------------------------
  34146      2013/04/17                    dog     Haute-Savoie         Urinary tract infection   ESBL; StrKanAprTobNetSss
  34381      2013/10/09                    dog     Alpes-Maritimes      Urinary tract infection   AmpC; Chl
  34955      2013/11/22                    horse   Oise                 Skin infection            ESBL; KanTobNetChlSssTmpNalEnr
  34956      2013/10/25                    horse   Calvados             Skin infection            ESBL; StrKanTobNetChlSssTmpNalEnr
  34958      2013/07/30                    dog     Paris                Urinary tract infection   ESBL; StrKanAmkAprGenTobNetChlSssTmpNalEnr
  36016      2013/11/05                    dog     Val-de-Marne         Abdominal infection       ESBL; StrKanAmkGenTobNetChlSssTmpNalEnr
  36017      2013/22/04                    dog     Val-de-Marne         Urinary tract infection   ESBL; StrKanGenTobNetChlSssTmpNalEnr
  36022      2013/11/10                    dog     Alpes-Maritimes      Urinary tract infection   StrSss
  36544      2014/03/05                    dog     Paris                Urinary tract infection   StrChlSssTmpNalEnr
  37427      2014/04/04                    dog     Val-de-Marne         Urinary tract infection   ESBL; KanGenTobNetChlSssTmpNalEnr
  37429      2014/03/14                    dog     Loire                Otitis                    StrKanGenTobChlSss
  37665      2014/04/22                    dog     Paris                Urinary tract infection   AmpC
  37666      2014/03/21                    dog     Val-de-Marne         Wound                     AmxStrKanGenTobSssTmpNalEnr
  38309      2014/09/09                    dog     Haute-Savoie         Unknown                   StrSssTmpNalEnr
  38317      2014/09/09                    dog     Tarn                 Otitis                    AmxStrKanGenTobChlSssTmpNalEnr
  38327      2014/09/29                    dog     Oise                 Skin infection            ESBL + AmpC; StrKanChlSssTmp
  38346      2014/07/09                    dog     Hauts-de-Seine       Urinary tract infection   AmxStrKanGenTobChlSss
  38356      2014/07/15                    dog     Aisne                Otitis                    StrChlSssTmpNalEnr
  38368      2014/08/21                    dog     Loire-Atlantique     Urinary tract infection   AmpC; ChlSssTmpNalEnr
  38375      2014/08/21                    dog     Côtes-d'Armor        Otitis                    AmpC; Chl
  38653      2014/11/03                    cat     Seine-St-Denis       Urinary tract infection   StrKanGenTobChlSss
  39081      2014/12/01                    dog     Val-de-Marne         Urinary tract infection   ESBL; StrKanAmkGenTobNetChlSssTmpNalEnr
  39165      2014/10/02                    cat     Loire-Atlantique     Urinary tract infection   AmpC; SssTmpNalEnr
  39175      2014/10/31                    dog     Val-de-Marne         Otitis                    AmpC; AprChlNal
  39193      2014/10/09                    dog     Paris                Otitis                    AmpC; StrChlTmpNal
  39214      2014/11/18                    dog     Val-de-Marne         Skin infection            AmpC; AprChlNal
  39219      2015/01/26                    dog     Somme                Unknown                   StrChlSssTmpNalEnr
  39465^c^   2014/09/19                    cat     Gironde              Unknown                   ESBL; SssTmpNalEnr
                                                                                                  

a

ESBL, extended-spectrum beta-lactamase; Amx, amoxicillin; Chl, chloramphenicol; Ffc, florfenicol; Amk, amikacin; Apr, apramycin; Gen, gentamicin; Tob, tobramycin; Net, netilmicin; Kan, kanamycin; Str, streptomycin; Sss, sulfonamides; Tmp, trimethoprim; Nal, nalidixic acid; Enr, enrofloxacin

.

b

French department: The department is the administrative subdivision of France

.

c

P. rettgeri

strain

.

Among the 11 SGI1-positive *P. mirabilis*, six showed an ESBL phenotype using the double disk synergy test by antibiogram. PCR mapping of the SGI1 resistance gene cluster and backbone revealed that all six ESBL-positive isolates harbored the SGI1-V variant carrying the *bla*~VEB-6~ gene (**Figure [1](#F1){ref-type="fig"}**). In the five other SGI1-positive *P. mirabilis* isolates, PCR mapping of the antimicrobial resistance gene cluster gave positive results for different complex class 1 integrons, i.e., InSGI1-H, In*Pm*ABB and In*Pm*MAT (**Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). PCR mapping of the SGI1 backbone confirmed that SGI1 elements with InSGI1-H, In*Pm*ABB, and In*Pm*MAT harbored the same 2789 bp deletion at position 5340-8120 (GenBank accession number AF261825) in the region spanning from ORF S005 to ORF S009, as previously described. Except for SGI1-In*Pm*MAT, this deletion was replaced by the insertion of IS*Vch4* (also called IS*1359*) (**Figure [1](#F1){ref-type="fig"}**). Interestingly, this region contains two ORFs S007 and S006 coding for homologs of the master activator AcaDC of IncA/C conjugative plasmids and named SgaDC (SGI1 activator, subunits D and C; [@B26]; [@B25]). The SgaDC activator (also named FlhDC~SGI1~) was shown to be active on the same AcaDC-dependent promoter regions, i.e., P*~xis~*, and thus should be also implicated in transfer and/or maintenance of SGI1 ([@B25]). The absence of *flhDC*~SGI1~ in these variants and the partial deletion of ORF S005 (*traN*) may have implications in their spread that needs to be further studied. In addition to the classical penta-resistance of SGI1 to amoxicillin, chloramphenicol, streptomycin and sulphonamides, other SGI1/PGI1-conferred resistances were amikacin, apramycin, gentamicin, tobramycin, netilmicin, kanamycin, nalidixic acid, trimethoprim, and enrofloxacin.

The six PGI1-positive *P. mirabilis* isolates were characterized by PCR mapping of the whole backbone. PCR products of the expected sizes were obtained for the complete mapping indicating a conserved PGI1 genetic structure in these isolates (**Figure [1](#F1){ref-type="fig"}**). All six isolates showed similar antibiotic resistance profiles as the ones previously described ([@B33]; [@B29]). Interestingly PGI1, which was only recently reported in *P. mirabilis*, was represented in more than one-third of the genomic islands characterized here, thus confirming the proportion observed in a recent study on a much smaller number of isolates ([@B29]). This may suggest either a previously undetected situation in the *Proteae* population or a recent and rapid spread of PGI1 elements, which were first described in 2014 ([@B33]). Our data also indicate that the dissemination of SGI1/PGI1 in multidrug-resistant *P. mirabilis* in animals is not a sporadic phenomenon and should be considered with great attention.

Extended-Spectrum and AmpC β-Lactamases
---------------------------------------

Eighteen strains (18/468, 3.8%) harbored an ESBL profile (*n* = 9), an AmpC profile (*n* = 8), or a combination of both (*n* = 1) after antibiotic susceptibility analysis. Only one AmpC-producing strain did not present any additional resistance (**Table [1](#T1){ref-type="table"}**). Otherwise, proportions of strains resistant to non-β-lactam antibiotics were particularly high for chloramphenicol (14/18, 77.8%), streptomycin (10/18, 55.6%), trimethoprim/sulphonamides (13/18, 72.2%), nalidixic acid (13/18, 72.2%), and enrofloxacin (10/18, 55.6%). Of note, none of the strains were resistant to carbapenems.

In addition to the six SGI1-V positive *P. mirabilis* described above, the ESBL phenotype was detected in four other strains. Two *P. mirabilis* isolates (38327 and 39081) harbored the *bla*~VEB-6~ gene independently of the SGI1 element (**Figure [2](#F2){ref-type="fig"}**), whereas the two last ESBL-producing isolates harbored the *bla*~CTX-M-15~ gene (*P. mirabilis* 34146) and the *bla*~CTX-M-1~ gene (*P. rettgeri* 39465). The prevalence of ESBL producers was lower than the one recently reported in France. However, the previous sampling was based on isolates conserved by the veterinary laboratories and a bias toward non-susceptible isolates cannot be excluded ([@B29]). On the contrary, no ESBL-producing isolate was detected in Japan ([@B15]). In any case, *Proteae* from animal origin present much less ESC-resistant isolates than those from human origin, since the nowadays ESBL rate in animals is very close to the French situation in human medicine in the late 1990s ([@B6]).

Concerning AmpC resistance phenotypes, the *bla*~CMY\ -2~ gene was detected alone in 7 *P. mirabilis* isolates whereas another *P. mirabilis* isolate (38375) presented a *bla*~DHA-16~ gene (**Figure [2](#F2){ref-type="fig"}**). Finally, one *P. mirabilis* isolate (39214) possessed both *bla*~CMY\ -2~ and *bla*~DHA-16~ genes (**Figure [2](#F2){ref-type="fig"}**). The presence of multiple ESC-resistance genes in two strains (*bla*~VEB-6~/*bla*~CMY\ -2~ in 38327 and *bla*~CMY\ -2~/*bla*~DHA-16~ in 39214) shows the capacity of *P. mirabilis* to accumulate redundant resistance genes and thus acting as a potential reservoir.

The chromosomal location of genes was assessed by Southern-blots on *I-Ceu*I-PFGE using the probes corresponding to the ESBL/AmpC genes carried by the studied isolates, as well as probes specific for the 23S rDNA. This method revealed that all *bla*~CMY\ -2~ (**Figure [3](#F3){ref-type="fig"}**) and *bla*~DHA-16~ genes (**Supplementary Figure [S1](#SM2){ref-type="supplementary-material"}**) were located on the bacterial chromosome. All *bla*~VEB-6~ genes carried by the SGI1-V variant as well as the *bla*~VEB-6~ gene identified in isolate 39081 were also proved to be encoded by the chromosome (**Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}**). On the contrary, the plasmidic localization of genes was proved by Southern-blots on S1-nuclease-PFGE using adequate probes. The last non-chromosomal *bla*~VEB-6~ (38327; **Supplementary Figure [S3](#SM2){ref-type="supplementary-material"}**) and *bla*~CTX-M-1~ (*P. rettgeri* 39465; **Figure [4](#F4){ref-type="fig"}**) genes were thus shown to be carried on plasmids, which were considered as non-typable because of the total absence of amplification using the PBRT kit. Finally, the *P. mirabilis* isolate 34146 carried two copies of the ESBL gene *bla*~CTX-M-15~, one located on the chromosome and the other on a non-typable plasmid (**Figure [4](#F4){ref-type="fig"}**). Whereas ESBL genes were mostly reported on plasmids in *Enterobacteriaceae*, it is noteworthy to observe that it is seemingly not the case in *Proteae*. These data strongly suggest that *Proteae* may be more prone than other *Enterobacteriaceae* to integrate resistance determinants into the chromosome, mostly on SGI1/PGI1 or other genomic islands.

![**Chromosomal localization of *bla*~CMY\ -2~ in the relevant *P. mirabilis* isolates.** **(A)** Whole genomic DNAs of isolates 34381 (lane1), 37665 (lane 2), 38327 (lane 3), 38368 (lane 4), 39165 (lane 5), 39175 (lane 6), 39193 (lane 7), and 39214 (lane 8) were digested with *I-Ceu*I, and the restricted fragments subjected to PFGE. DNA fragments were transferred to a nylon membrane and hybridized with probes specific to *bla*~CMY\ -2~ **(B)**, and the 23S rRNA gene **(C)**. The arrows indicate the bands of interest.](fmicb-08-00032-g003){#F3}

![**Plasmidic localization of *bla*~CTX-M-1\ group~ genes in the relevant isolates.** **(A)** Whole genomic DNAs of a CTX-M-15-carrying *E. coli* isolate used as a positive control (lane 1), *P. mirabilis* isolate 34146 (lane 2), and *P. rettgeri* isolate 39465 (lane 3), were digested with S1-nuclease, and the restricted fragments subjected to PFGE. DNA fragments were transferred to a nylon membrane and hybridized with a probe specific to *bla*~CTX-M~ **(B)**. The arrows indicate the bands of interest.](fmicb-08-00032-g004){#F4}

Genetic Diversity of the Isolates
---------------------------------

*Sma*I PFGE revealed that all SGI1/PGI1-positive isolates were genetically unrelated as were the ESBL/AmpC producing isolates (**Figure [2](#F2){ref-type="fig"}**), except the six SGI1-V positive isolates that belonged to the same cluster but interestingly differed from the ones previously reported ([@B29]). This clustering suggests the spread of a clonal population among different and unrelated individuals. Such a dominance of a clonal population of SGI1-V/*bla*~VEB-6~ *P. mirabilis* strains in humans and companion animals may result from close contacts between these two populations, as also demonstrated for the transfer of other multidrug resistant bacteria or plasmids, such as those carrying ESBL genes. Indeed, the transmission of bacterial clones from animals to humans (or vice-versa) through physical contacts or contact with contaminated saliva or feces has been described ([@B12]; [@B23]).

Conclusion
==========

In this study, we showed a significant prevalence rate (∼4%) of ESBLs/AmpC in *P. mirabilis* of animal sources. A long-term survey is now needed to decipher whether these are emerging phenotypes or only sporadic cases. The multidrug resistance genomic islands SGI1 and PGI1 play a major role in the dissemination of ESBLs/AmpC genes as well as other non-β-lactam resistance genes. Moreover, we report the spread of the SGI1-V/*bla*~VEB-6~-carrying *P. mirabilis* clonal population to horses. This peculiar ESBL-producing *P. mirabilis* population was previously recognized in humans and dogs and highly suspected in poultry isolates ([@B30]). Altogether, these data suggest an inter-transmission pathway of public health relevance that needs further investigations to be clarified. Therefore, *P. mirabilis* should be regarded as a potential reservoir of resistance traits in companion animals making us believe that veterinarians should pay more attention to *P. mirabilis* as an opportunistic multidrug-resistant pathogen.
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